Business
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON, May 08, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c79251eb98bd2b094d402d8791680841"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SxU6EPFx5q9knIzwK1AfQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c79251eb98bd2b094d402d8791680841","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kM2xzYxlfONeHsmfXhnftQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c79251eb98bd2b094d402d8791680841","width":1024,"height":512}},"lazy":false},{"type":"text","content":"– Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg –","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"– FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 –","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"– CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 –","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 08, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.","length":362,"tagName":"p"},{"type":"text","content":""Our EDO platform’s unique ability to efficiently deliver oligonucleotides into the nuclei of cells is the foundation of our differentiated pipeline, with promising clinical data from two programs underscoring what we believe to be the broad potential of our technology," said James McArthur, PhD, President and CEO of PepGen. "This is a pivotal and catalyst-rich 12 months for PepGen and for our DM1 and DMD clinical programs. Following the highly encouraging initial results from our FREEDOM-DM1 study reported in February, demonstrating potentially best-in-class splicing correction after a single therapeutic dose, we look forward to sharing data from the 15 mg/kg cohort in the second half of the ...